A Phase 3 clinical trial involving tirzepatide has reached completed status as of September 4, 2026. The study, registered as NCT06221969, is titled "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor."
The trial was designed to compare CagriSema against tirzepatide in people with type 2 diabetes who were being treated with metformin, with or without an SGLT2 inhibitor. It examined outcomes related to blood sugar and body weight in this patient population.
The study status is listed as COMPLETED in the trial record. No results have been reported in this update, and this brief does not characterize or summarize any outcomes, findings, or comparative performance between the two treatments. The classification of this update reflects only the trial's status, phase, and title as recorded.
Tirzepatide remains an approved compound. This update pertains specifically to its evaluation within this registered Phase 3 clinical trial. For more background on tirzepatide, readers can consult the compound overview.